Although the KRAS proto-oncogene point mutation occurs in 90% of PC (32, 33), the unique activities of EGFR were demonstrated to promote cancer progression even when KRAS is mutated in PC cell lines (34–38). Here, KRAS is linked to pachyonychia congenita.